KR20200093621A - 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 - Google Patents

혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 Download PDF

Info

Publication number
KR20200093621A
KR20200093621A KR1020207018642A KR20207018642A KR20200093621A KR 20200093621 A KR20200093621 A KR 20200093621A KR 1020207018642 A KR1020207018642 A KR 1020207018642A KR 20207018642 A KR20207018642 A KR 20207018642A KR 20200093621 A KR20200093621 A KR 20200093621A
Authority
KR
South Korea
Prior art keywords
weeks
dose
patient
diabetic retinopathy
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207018642A
Other languages
English (en)
Korean (ko)
Inventor
로버트 엘 비티
앨리슨 제이 베를리너
카렌 츄
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64755724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200093621(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Priority to KR1020247015825A priority Critical patent/KR20240074890A/ko
Publication of KR20200093621A publication Critical patent/KR20200093621A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020207018642A 2017-11-30 2018-11-29 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 Ceased KR20200093621A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247015825A KR20240074890A (ko) 2017-11-30 2018-11-29 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762593033P 2017-11-30 2017-11-30
US62/593,033 2017-11-30
US201862644425P 2018-03-17 2018-03-17
US62/644,425 2018-03-17
US201862748782P 2018-10-22 2018-10-22
US62/748,782 2018-10-22
PCT/US2018/063025 WO2019108770A1 (en) 2017-11-30 2018-11-29 Use of a vegf antagonist to treat angiogenic eye disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015825A Division KR20240074890A (ko) 2017-11-30 2018-11-29 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도

Publications (1)

Publication Number Publication Date
KR20200093621A true KR20200093621A (ko) 2020-08-05

Family

ID=64755724

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207018642A Ceased KR20200093621A (ko) 2017-11-30 2018-11-29 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
KR1020247015825A Pending KR20240074890A (ko) 2017-11-30 2018-11-29 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247015825A Pending KR20240074890A (ko) 2017-11-30 2018-11-29 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도

Country Status (25)

Country Link
US (3) US10973879B2 (https=)
EP (4) EP4122486A1 (https=)
JP (3) JP7339248B2 (https=)
KR (2) KR20200093621A (https=)
CN (1) CN111465407A (https=)
AU (2) AU2018375398C1 (https=)
BR (1) BR112020010659A2 (https=)
CA (1) CA3083611A1 (https=)
DK (1) DK3716992T3 (https=)
ES (1) ES2927049T3 (https=)
HR (1) HRP20221335T1 (https=)
HU (1) HUE059827T2 (https=)
IL (3) IL312323B1 (https=)
LT (1) LT3716992T (https=)
MX (1) MX2020005166A (https=)
MY (1) MY201127A (https=)
NZ (1) NZ764953A (https=)
PL (1) PL3716992T3 (https=)
PT (1) PT3716992T (https=)
RS (1) RS63703B1 (https=)
SG (1) SG11202004268PA (https=)
SI (1) SI3716992T1 (https=)
SM (1) SMT202200374T1 (https=)
WO (1) WO2019108770A1 (https=)
ZA (1) ZA202002821B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
WO2022120168A1 (en) * 2020-12-04 2022-06-09 Genentech, Inc. Automated screening for diabetic retinopathy severity using color fundus image data
AU2022251523A1 (en) * 2021-03-31 2023-09-28 Hangzhou Exegenesis Bio Ltd. Fusion molecules targeting vegf and angiopoietin and uses thereof
KR20240008821A (ko) * 2021-05-17 2024-01-19 리제너론 파아마슈티컬스, 인크. 혈관신생성 눈 장애 치료를 위한 연장된 고용량 vegf 길항제 요법
IL315347A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN120060370A (zh) * 2023-11-29 2025-05-30 上海科锐克医药科技有限公司 用于递送人vegf受体融合蛋白的基因递送载体及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2262817A1 (en) 1996-08-19 1998-02-26 James Robl Embryonic or stem-like cell lines produced by cross species nuclear transplantation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
JP2005511576A (ja) 2001-11-09 2005-04-28 アイテック・ファーマシューティカルズ 眼球血管新生病を治療する方法
AU2003226349B2 (en) 2002-04-11 2008-01-31 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
WO2004072320A2 (en) 2003-02-07 2004-08-26 Pavco, Inc. Use of n-allyl substituted amines and their salts as brightening agents in nickel plating baths
WO2004087206A2 (en) 2003-03-28 2004-10-14 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking vegf-mediated activity
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
WO2004103159A2 (en) 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
CA2519835A1 (en) 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
EP1732947B1 (en) 2004-03-05 2011-04-27 Vegenics Pty Ltd Growth factor binding constructs materials and methods
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CA2567686A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
MXPA06014689A (es) 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
CA2615636A1 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US20100111963A1 (en) 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
EP3010526A1 (en) * 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating macular edema
DK4374873T3 (da) * 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
MX368442B (es) 2014-01-25 2019-10-02 Chengdu Kanghong Biotechnologies Co Ltd Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma.
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CA2989270A1 (en) 2015-06-16 2016-12-22 Translatum Medicus, Inc. Compositions and methods for treating and diagnosing ocular disorders
PE20181363A1 (es) 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
EP3377100B1 (en) * 2015-11-18 2025-02-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
EP3380121B1 (en) 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
DE102017210134A1 (de) 2016-12-15 2018-06-21 Fresenius Medical Care Deutschland Gmbh System zur extrakorporalen Blutbehandlung, Behandlungsvorrichtung, Kit und Verfahren zum Betreiben eines Systems zur extrakorporalen Blutbehandlung
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein

Also Published As

Publication number Publication date
RS63703B1 (sr) 2022-11-30
US12280093B2 (en) 2025-04-22
EP4279135A3 (en) 2024-02-21
LT3716992T (lt) 2022-09-12
US20210205410A1 (en) 2021-07-08
US20190290725A1 (en) 2019-09-26
US10973879B2 (en) 2021-04-13
MY201127A (en) 2024-02-07
IL312323B1 (en) 2026-04-01
JP7339248B2 (ja) 2023-09-05
SI3716992T1 (sl) 2022-10-28
PL3716992T3 (pl) 2022-12-19
HUE059827T2 (hu) 2023-01-28
SG11202004268PA (en) 2020-06-29
HRP20221335T1 (hr) 2022-12-23
AU2018375398C1 (en) 2026-01-15
ZA202002821B (en) 2021-08-25
EP4122486A1 (en) 2023-01-25
DK3716992T3 (da) 2022-09-12
IL274711B2 (en) 2024-10-01
JP2023159323A (ja) 2023-10-31
IL312323A (en) 2024-06-01
IL326641A (en) 2026-04-01
PT3716992T (pt) 2022-08-31
AU2025201179A1 (en) 2025-03-13
MX2020005166A (es) 2020-09-03
BR112020010659A2 (pt) 2020-11-10
ES2927049T3 (es) 2022-11-02
CN111465407A (zh) 2020-07-28
CA3083611A1 (en) 2019-06-06
JP2025069279A (ja) 2025-04-30
KR20240074890A (ko) 2024-05-28
JP2021505535A (ja) 2021-02-18
IL274711A (en) 2020-07-30
WO2019108770A1 (en) 2019-06-06
US20250268983A1 (en) 2025-08-28
EP3716992B1 (en) 2022-08-10
AU2018375398B2 (en) 2024-11-21
IL274711B1 (en) 2024-06-01
AU2018375398A1 (en) 2020-06-18
EP4609914A2 (en) 2025-09-03
EP4279135A2 (en) 2023-11-22
NZ764953A (en) 2026-03-27
EP3716992A1 (en) 2020-10-07
EP4609914A3 (en) 2025-10-15
SMT202200374T1 (it) 2022-11-18

Similar Documents

Publication Publication Date Title
KR20200093621A (ko) 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
KR20140043313A (ko) 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
KR20210021299A (ko) 고농도 vegf 수용체 융합 단백질 함유 제제
KR20240008821A (ko) 혈관신생성 눈 장애 치료를 위한 연장된 고용량 vegf 길항제 요법
KR20230135012A (ko) 혈관형성 눈 장애의 치료를 위한 연장된 고 용량 vegf 길항제 용법
HK40094966A (en) Use of a vegf antagonist to treat diabetic retinopathy
CN117642175A (zh) 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
HK40125761A (en) Use of a vegf antagonist to treat angiogenic eye disorders
EA046420B1 (ru) Применение антагониста vegf для лечения ангиогенных глазных заболеваний
HK40038974A (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK40038974B (en) Use of a vegf antagonist to treat angiogenic eye disorders
NZ612593B2 (en) Use of a vegf antagonist to treat angiogenic eye disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211129

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240313

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240517

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20240313

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I